Is tocilizumab truly beneficial for COVID-19 patients?

  • Dr. Josef Finsterer Klinik Landstrasse, Messerli Institute, Austria.
Keywords: SARS-CoV-2, COVID-19, Tocilizumab, Treatment, Weakness

Abstract

No abstract for this paper is available.

Downloads

Download data is not yet available.

Author Biography

Dr. Josef Finsterer, Klinik Landstrasse, Messerli Institute, Austria.

MD, PhD

Published
2021-02-28
How to Cite
Finsterer, D. J. (2021). Is tocilizumab truly beneficial for COVID-19 patients?. International Journal of Medical Studies, 6(2), 39-40. Retrieved from http://ijmsonline.in/index.php/ijms/article/view/186
Issue
Vol 6 No 2 (2021): International Journal of Medical Studies (PRINT ISSN 2542:2766)
Section
Letter to the Editor

Copyright (c) 2021 Author

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The Authors retain copyright (full ownership) to their content published in the Journal. We claim no intellectual property rights over the material provided by any User in this Journal. However, by setting pages to be viewed publicly (Open Access), the User agrees to allow others to view and download the relevant content. In addition, Open Access articles might be used by the Provider, or any other third party, for data mining purposes.

The Provider reserves the rights in its sole discretion to refuse or remove any content that is available via the Website.

Most read articles by the same author(s)